Chip Holbrook, MD
Family Medicine · Mendenhall, MSNPI 1962546192
Payments from drug & device makers
Across 160 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$494
- Novo Nordisk$393
- GSK$365
- Lilly USA, LLC$250
- Boehringer Ingelheim$246
- Amgen$125
- plus $949 from 22 others
What the payments were for
- Food & beverage$2,815100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $494 |
| Novo Nordisk | 24 | $393 |
| GSK | 24 | $365 |
| Lilly USA, LLC | 15 | $250 |
| Boehringer Ingelheim | 14 | $246 |
| Amgen | 8 | $125 |
| Merck | 7 | $111 |
| Avanir Pharmaceuticals, Inc. | 2 | $104 |
| Kowa Pharmaceuticals America, Inc. | 5 | $87 |
| AbbVie | 5 | $75 |
| Novartis | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 4 | $62 |
| Mylan Specialty L.p. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Abbott | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Shield Therapeutics Inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Purdue Pharma L.p. | 1 | $19 |
| Bayer | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$250
- FARXIGA$115
How this compares
$2,822 in reported general payments places this provider in the 75th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 562 | $229,166 |
| JardianceEmpagliflozin | 422 | $200,901 |
| OzempicSemaglutide | 142 | $140,149 |
| FarxigaDapagliflozin Propanediol | 272 | $114,169 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $59,859 |
| TrulicityDulaglutide | 47 | $45,359 |
| EntrestoSacubitril/Valsartan | 73 | $43,619 |
| MyrbetriqMirabegron | 96 | $31,923 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 38 | $31,506 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $30,995 |
| UbrelvyUbrogepant | 16 | $29,283 |
| XareltoRivaroxaban | 60 | $27,763 |
| LinzessLinaclotide | 49 | $27,214 |
| Sevelamer Carbonate | 21 | $23,023 |
| JanuviaSitagliptin Phosphate | 42 | $22,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $229,166562 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $246 | $211,217443 claims |
| Novo NordiskOzempic | $393 | $140,149142 claims |
| AstraZenecaFarxiga, Symbicort | $494 | $123,782312 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $365 | $111,065238 claims |
| AbbVieUbrelvy, Linzess | $75 | $56,49665 claims |
| Lilly USA, LLCTrulicity | $250 | $45,35947 claims |
| NovartisEntresto | $65 | $43,61973 claims |
| MerckJanuvia, Janumet Xr | $111 | $29,37768 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $39 | $16,79938 claims |
| AmgenCorlanor | $125 | $7,56315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Mendenhall
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.